CompletedPhase 3NCT01614457

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vertex Pharmaceuticals Incorporated
Principal Investigator
Richard Moss, MD
Stanford University
Intervention
Ivacaftor(drug)
Enrollment
70 enrolled
Eligibility
6 years · All sexes
Timeline
20122013

Study locations (30)

Collaborators

Cystic Fibrosis Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01614457 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis

← Back to all trials